Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

INDP

Indaptus Therapeutics (INDP)

Indaptus Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:INDP
DateTimeSourceHeadlineSymbolCompany
01/31/20253:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
01/22/20254:01PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:INDPIndaptus Therapeutics Inc
01/14/20253:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
01/13/20257:00AMGlobeNewswire Inc.Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:INDPIndaptus Therapeutics Inc
01/08/20257:00AMGlobeNewswire Inc.Indaptus Therapeutics Provides Year-End Review and Outlook for 2025NASDAQ:INDPIndaptus Therapeutics Inc
01/01/202511:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:INDPIndaptus Therapeutics Inc
12/23/20243:52PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:INDPIndaptus Therapeutics Inc
12/06/20243:36PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:INDPIndaptus Therapeutics Inc
11/22/20243:48PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
11/22/20243:23PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:INDPIndaptus Therapeutics Inc
11/22/20247:36AMGlobeNewswire Inc.Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:INDPIndaptus Therapeutics Inc
11/12/20247:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
11/12/20247:00AMGlobeNewswire Inc.Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
11/11/20247:00AMGlobeNewswire Inc.Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in ImmunologyNASDAQ:INDPIndaptus Therapeutics Inc
11/07/20247:00AMGlobeNewswire Inc.Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
10/23/20247:00AMGlobeNewswire Inc.Indaptus Therapeutics to Present at Two Upcoming Investor ConferencesNASDAQ:INDPIndaptus Therapeutics Inc
10/22/20247:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
10/22/20247:00AMGlobeNewswire Inc.Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment CombinationsNASDAQ:INDPIndaptus Therapeutics Inc
10/15/20247:00AMGlobeNewswire Inc.Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety DataNASDAQ:INDPIndaptus Therapeutics Inc
10/10/20243:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INDPIndaptus Therapeutics Inc
10/10/20247:00AMGlobeNewswire Inc.Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer ImmunotherapyNASDAQ:INDPIndaptus Therapeutics Inc
10/08/20247:00AMGlobeNewswire Inc.Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitNASDAQ:INDPIndaptus Therapeutics Inc
10/04/20244:21PMEdgar (US Regulatory)Form D/A - Notice of Exempt Offering of Securities: [Amend]NASDAQ:INDPIndaptus Therapeutics Inc
09/22/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:INDPIndaptus Therapeutics Inc
09/12/20243:45PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:INDPIndaptus Therapeutics Inc
09/05/20247:30AMGlobeNewswire Inc.Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different DosesNASDAQ:INDPIndaptus Therapeutics Inc
09/03/20247:00AMGlobeNewswire Inc.Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
08/22/20249:06AMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:INDPIndaptus Therapeutics Inc
08/12/20247:16AMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:INDPIndaptus Therapeutics Inc
08/12/20247:01AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INDPIndaptus Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:INDP